logo
Plus   Neg
Share
Email

AstraZeneca, Eli Lilly To Discontinue Lanabecestat Trials In Alzheimer's

AstraZeneca (AZN.L,AZN) and Eli Lilly and Company announced they are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease. The decision is based on recommendations by an independent data monitoring committee. The committee concluded that both the AMARANTH trial, in early Alzheimer's disease, and the DAYBREAK-ALZ trial, in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints upon completion.

The AstraZeneca and Lilly BACE alliance for lanabecestat remains in place and the companies will now work with the clinical trial sites involved to implement the discontinuations.

AstraZeneca said the discontinuation of the lanabecestat Phase III clinical trials in Alzheimer's disease is not expected to have a material impact on the company's financial guidance for 2018, which therefore remains unchanged.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Danske Bank A/S's Chief Executive Thomas Borgen resigned on Wednesday after the Danish lender announced the results of an internal probe relating to a money-laundering scandal in its branch in Estonia that involved payments of about 200 billion euros. Danske Bank said its investigation covered about 15,000 customers and a total of around 9.5 million payments through the branch. The Competition and Markets Authority (CMA) in the United Kingdom confirmed Wednesday that the proposed merger between J Sainsbury plc (JSAIY.PK, SBRY.L) and Asda Group Ltd. is being referred for an in-depth Phase 2 investigation. CMA noted that the deal raises sufficient concerns through its Phase... BMW plans to shut down the Mini factory in Oxford for a month after Brexit to minimize supply disruption in case there is no deal. The German auto giant said its annual maintenance shutdown at the site in Cowley, Oxford will be brought forward to April 1 to reduce any "possible short-term parts-supply...
Follow RTT